=> => : upamfva 16 2022, 03:29:34

: Novartis puts contract manufacturing ambitions on display
: upamfva 16 2022, 03:29:34
Novartis puts contract manufacturing ambitions on display

It turns out Novartis has a taste for the contract manufacturing business. After inking a slate of pandemic production pacts last year, the Swiss pharma is back for anotherand this time, its looking beyond COVID-19.To get more novartis news (https://www.shine.cn/tags/novartis/), you can visit shine news official website.

Novartis has penned an initial deal to manufacture Carisma Therapeutics HER2-targeted CAR-M cell therapy, which is currently in initial studies to treat solid tumors.

Under the deal, Carisma will begin transferring its manufacturing process to a Novartis Cell Therapy site in Morris Plains, New Jersey, starting in the coming days, Novartis said Thursday. The drug giant aims to kick off clinical manufacturing of the cell therapy candidate next year.As one of the worlds largest producers of medicines, Novartis can mobilize its manufacturing capacity in an efficient way on multiple fronts, Anton Gerdenitsch, head of Novartis Technical Operations contract manufacturing organization, said in a statement.

Novartis says it will continue to lend its manufacturing muscle to other companies, adding that [f]urther specifics will be disclosed when agreements are concluded.

So far, the companys contract manufacturing ambitions have focused squarely on COVID-19.Last year, Novartis agreed to chip in on production of Pfizer and BioNTechs mRNA-based vaccine Comirnaty, helping fill shots at sites in Switzerland and Slovenia. The company also signed an initial manufacturing agreement with German mRNA specialist CureVac last March, and it penned a deal in April to reserve active pharmaceutical ingredient capacity for Roches rheumatoid arthritis med Actemra in Singapore.

CAR-M therapies, meanwhile, arent all that different from CAR-T therapies such as Novartis cancer med Kymriah. For the manufacturing process, immune cells are extracted from patients, modified and then infused back in. Unlike CAR-T therapies, however, CAR-Ms are made of macrophages.

As Novartis revs up its contract manufacturing operations, the fate of its generics outfit Sandoz remains undecided. In October, the Swiss pharma kicked off a strategic review of the business unit, noting that all options were on the table, including retaining the business and a potential separation.